Hemfosa Fastigheter AB (publ) (“Hemfosa” or “the Company”) has appointed ABG Sundal Collier, SEB and Swedbank to explore the conditions for conducting a directed share issue in the total amount of up to 10 million shares (the “Share Issue”) through an accelerated bookbuilding procedure, (the “Bookbuilding”). If conducted, the Share Issue will be directed towards Swedish and international institutional investors, and executed with the authorisation given by the annual general meeting held on 18 April 2018. The purpose of the Share Issue is to provide the Company with additional equity capital in a quick and efficient manner in order to utilize current business opportunities and optimise the capital structure ahead of a contemplated split of the group.
The Share Issue is, among other things, subject to a resolution by the board of directors of Hemfosa, pursuant to the issue authorization given by the annual general meeting held on 18 April 2018 to issue new shares, following the close of the Bookbuilding. The Board of Directors can at any time choose to terminate the Bookbuilding and refrain from executing the Share Issue.
Important information
Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Hemfosa in any jurisdiction.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to the United States, Canada, Australia, South Africa, Japan, Hong Kong, Switzerland, Singapore, New Zealand or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.
This press release is not a prospectus. Hemfosa has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been prepared or will be prepared in connection with the directed new share issue.
For more information, please contact:
Bengt Kjell, chairman of the board, cellphone +46 (0)70-594 5398